1. 3072 Phase 2: Docetaxel with or without ramucirumab as therapy for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations after prior EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy. (September 2015) Authors: Kasahara, K.; Kiura, K.; Nogami, N.; Takayama, K.; Takiguchi, Y.; Hirashima, T.; Aoe, K.; Hayashi, H.; Saka, H.; Takahashi, K.; Imamura, F.; Oizumi, S.; Inoue, A.; Satouchi, M.; Tatsumi, M.; Nakamura, T.; Enatsu, S.; Tamura, T.; Nakagawa, K. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S620 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Association of immunoglobulin G4 and free light chain with idiopathic pleural effusion. (17th July 2017) Authors: Murata, Y.; Aoe, K.; Mimura‐Kimura, Y.; Murakami, T.; Oishi, K.; Matsumoto, T.; Ueoka, H.; Matsunaga, K.; Yano, M.; Mimura, Y. Journal: Clinical and experimental immunology Issue: Volume 190:Number 1(2017:Oct.) Page Start: 133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗